Dendritic cell-based active specific immunotherapy for malignant glioma

Bibliography

• PARAJULI P, SLOAN AE: Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest. (2004) 22(3):405-416.
   PubMed Web of Science ®Google Scholar
• NIEDER C, ADAM M, MOLLS M, GROSU AL: Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. (2006) 60(3):181-193.
   PubMed Web of Science ®Google Scholar
• PALANICHAMY K, ERKKINEN M, CHAKRAVARTI A: Predictive and prognostic markers in human glioblastomas. Curr. Treat. Options Oncol. (2006) 7(6):490-504.
   PubMedGoogle Scholar
• CARPENTIER A, LAIGLE-DONADEY F, ZOHAR S et al.: Phase I trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neurooncology (2006) 8(1):60-66.
   Google Scholar
• BOIARDI A, SILVANI A, RUFFINI PA et al.: Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. (1994) 39(3):193-197.
   PubMed Web of Science ®Google Scholar
• JACOBS SK, WILSON DJ, KORNBLITH PL, GRIMM EA: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res. (1986) 46(4 Pt 2):2101-2104.
   PubMed Web of Science ®Google Scholar
• LICHTOR T, GLICK RP: Cytokine immuno-gene therapy for treatment of brain tumors. J. Neurooncol. (2003) 65(3):247-259.
   PubMed Web of Science ®Google Scholar
• MERCHANT RE, MCVICAR DW, MERCHANT LH, YOUNG HF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a Phase I clinical trial. J. Neurooncol. (1992) 12(1):75-83.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, DUMA CM, SCHILTZ PM et al.: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. (2004) 27(5):398-404.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA E, TSUBOI K, SAIJO K et al.: Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. (2004) 24(3b):1861-1871.
   PubMed Web of Science ®Google Scholar
• PLAUTZ GE, MILLER DW, BARNETT GH et al.: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. (2000) 6(6):2209-2218.
   PubMed Web of Science ®Google Scholar
• SLOAN AE, DANSEY R, ZAMORANO L et al.: Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus (2000) 9(6):e9.
   PubMedGoogle Scholar
• WOOD GW, HOLLADAY FP, TURNER T, WANG YY, CHIGA M: A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J. Neurooncol. (2000) 48(2):113-120.
   PubMed Web of Science ®Google Scholar
• REICHARDT VL, BROSSART P, KANZ L: Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. (2004) 18(4):235-243.
   PubMed Web of Science ®Google Scholar
• NENCIONI A, BROSSART P: Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells (2004) 22(4):501-513.
   PubMed Web of Science ®Google Scholar
• PARAJULI P, MATHUPALA S, SLOAN AE: Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery (2004) 55(5):1194-1204.
   PubMed Web of Science ®Google Scholar
• YU JS, WHEELER CJ, ZELTZER PM et al.: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. (2001) 61(3):842-847.
   PubMed Web of Science ®Google Scholar
• LIAU LM, PRINS RM, KIERTSCHER SM et al.: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. (2005) 11(15):5515-5525.
   PubMed Web of Science ®Google Scholar
• WHEELER CJ, DAS A, LIU G, YU JS, BLACK KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. (2004) 10(16):5316-5326.
   PubMed Web of Science ®Google Scholar
• OKADA H, POLLACK IF, LIEBERMAN F et al.: Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum. Gene Ther. (2001) 12(5):575-595.
   PubMed Web of Science ®Google Scholar
• OKADA H, LIEBERMAN FS, EDINGTON HD et al.: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. (2003) 64(1-2):13-20.
   PubMed Web of Science ®Google Scholar
• YAMANAKA R, ABE T, YAJIMA N et al.: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer (2003) 89(7):1172-1179.
   PubMed Web of Science ®Google Scholar
• YAMANAKA R, HOMMA J, YAJIMA N et al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. (2005) 11(11):4160-4167.
   PubMed Web of Science ®Google Scholar
• RUTKOWSKI S, DE VLEESCHOUWER S, KAEMPGEN E et al.: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer (2004) 91(9):1656-1662.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, AKASAKI Y, IRIE M et al.: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50(7):337-344.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, AKASAKI Y, ABE T et al.: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. (2004) 27(6):452-459.
   PubMed Web of Science ®Google Scholar
• GALON J, COSTES A, SANCHEZ-CABO F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960-1964.
   PubMed Web of Science ®Google Scholar
• FECCI PE, MITCHELL DA, WHITESIDES JF et al.: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. (2006) 66(6):3294-3302.
   PubMed Web of Science ®Google Scholar
• FACOETTI A, NANO R, ZELINI P et al.: Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. (2005) 11(23):8304-8311.
   PubMed Web of Science ®Google Scholar
• ROSZMAN TL, BROOKS WH: Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol. (1980) 39(2):395-402.
   Google Scholar
• GOMEZ GG, KRUSE CA: Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther. Mol. Biol. (2006) 10(a):133-146.
   PubMed Web of Science ®Google Scholar
• RAPP M, OZCAN Z, STEIGER HJ et al.: Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J. Neurosurg. (2006) 105(1):41-50.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER J, HOFMAN FM, APUZZO ML, HINTON DR: Cytokines and immunoregulatory molecules in malignant glial neoplasms. J. Neurosurg. (1992) 77(2):265-273.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER T, SAILER M, ANSORGE S, FIRSCHING R, REINHOLD D: Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J. Neurooncol. (2006) 79(1):61-65.
   PubMed Web of Science ®Google Scholar
• YAMADA N, KATO M, YAMASHITA H et al.: Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int. J. Cancer (1995) 62(4):386-392.
   PubMed Web of Science ®Google Scholar
• WICK W, NAUMANN U, WELLER M: Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des. (2006) 12(3):341-349.
   PubMed Web of Science ®Google Scholar
• COULDWELL WT, DORE-DUFFY P, APUZZO ML, ANTEL JP: Malignant glioma modulation of immune function: relative contribution of different soluble factors. J. Neuroimmunol. (1991) 33(2):89-96.
   PubMed Web of Science ®Google Scholar
• JENNINGS MT, MACIUNAS RJ, CARVER R et al.: TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int. J. Cancer (1991) 49(1):129-139.
   PubMed Web of Science ®Google Scholar
• JENSEN RL: Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg. Neurol. (1998) 49(2):189-195; discussion 196.
   PubMed Web of Science ®Google Scholar
• LAMSZUS K, HEESE O, WESTPHAL M: Angiogenesis-related growth factors in brain tumors. Cancer Treat. Res. (2004) 117:169-190.
   PubMedGoogle Scholar
• HULSHOF MC, SMINIA P, BARTEN-VAN RIJBROEK AD, GONZALEZ GONZALEZ D: Prognostic value of plasma transforming growth factor-beta in patients with glioblastoma multiforme. Oncology Rep. (2001) 8(5):1107-1110.
   PubMed Web of Science ®Google Scholar
• PAULUS W, BAUR I, HUETTNER C et al.: Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J. Neuropathol. Exp. Neurol. (1995) 54(2):236-244.
   PubMed Web of Science ®Google Scholar
• PLATTEN M, WICK W, WELLER M: Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. (2001) 52(4):401-410.
   Google Scholar
• FONTANA A, CONSTAM DB, FREI K, MALIPIERO U, PFISTER HW: Modulation of the immune response by transforming growth factor beta. Int. Arch. Allergy Immunol. (1992) 99(1):1-7.
   PubMed Web of Science ®Google Scholar
• GAJEWSKI TF, MENG Y, BLANK C et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. (2006) 213:131-145.
   PubMed Web of Science ®Google Scholar
• GORELIK L, CONSTANT S, FLAVELL RA: Mechanism of transforming growth factor beta-induced inhibition of T helper Type 1 differentiation. J. Exp. Med. (2002) 195(11):1499-1505.
   PubMed Web of Science ®Google Scholar
• INGE TH, HOOVER SK, SUSSKIND BM, BARRETT SK, BEAR HD: Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. (1992) 52(6):1386-1392.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, TENG MW, SWANN J et al.: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. (2006) 176(3):1582-1587.
   PubMed Web of Science ®Google Scholar
• EISELE G, WISCHHUSEN J, MITTELBRONN M et al.: TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain (2006) 129(Pt 9):2416-2425.
   PubMed Web of Science ®Google Scholar
• MORETTA L, BOTTINO C, PENDE D et al.: Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol. Lett. (2005) 100(1):7-13.
   PubMed Web of Science ®Google Scholar
• BERTONE S, SCHIAVETTI F, BELLOMO R et al.: Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. (1999) 29(1):23-29.
   PubMed Web of Science ®Google Scholar
• BEYER M, SCHULTZE JL: Regulatory T cells in cancer. Blood (2006) 108(3):804-811.
   PubMed Web of Science ®Google Scholar
• AKASAKI Y, LIU G, CHUNG NH et al.: Induction of a CD4+ T regulatory Type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. (2004) 173(7):4352-4359.
   PubMed Web of Science ®Google Scholar
• CHEN ZM, O’SHAUGHNESSY MJ, GRAMAGLIA I et al.: IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood (2003) 101(12):5076-5083.
   PubMed Web of Science ®Google Scholar
• ANDALOUSSI AE, LESNIAK MS: An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncology (2006) 8(3):234-243.
   PubMed Web of Science ®Google Scholar
• WALKER DG, CHUAH T, RIST MJ, PENDER MP: T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J. Neuroimmunol. (2006) 175(1-2):59-68.
   PubMed Web of Science ®Google Scholar
• KWON D, CHEONG JH, LEE JC, KWON JH, KIM WK: Lipopolysaccharides-activated human astroglioma cells induce apoptotic death of T-lymphocytes via c-Jun N-terminal kinases-dependent up-regulation of TRAIL. Neurosci. Res. (2006) 54(4):338-343.
   PubMed Web of Science ®Google Scholar
• ROTH P, AULWURM S, GEKEL I et al.: Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. Cancer Res. (2006) 66(7):3852-3858.
   PubMed Web of Science ®Google Scholar
• TANG J, FLOMENBERG P, HARSHYNE L, KENYON L, ANDREWS DW: Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin. Cancer Res. (2005) 11(14):5292-5299.
   PubMed Web of Science ®Google Scholar
• YOSHIDA S, TANAKA R: Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors. J. Lab. Clin. Med. (2004) 144(4):201-207.
   PubMed Web of Science ®Google Scholar
• DE VLEESCHOUWER S, ARREDOUANI M, ADE M et al.: Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol. Immunother. (2005) 54(4):372-382.
   PubMed Web of Science ®Google Scholar
• GRAUER O, POSCHL P, LOHMEIER A, ADEMA GJ, BOGDAHN U: Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J. Neurooncol. (2006) (In Press).
   PubMedGoogle Scholar
• JACHIMCZAK P, BOGDAHN U, SCHNEIDER J et al.: The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. (1993) 78(6):944-951.
   PubMed Web of Science ®Google Scholar
• LIU Y, WANG Q, KLEINSCHMIDT-DEMASTERS BK, FRANZUSOFF A, NG KY, LILLEHEI KO: TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J. Neurooncol. (2006) 81(2):149-162.
   PubMed Web of Science ®Google Scholar
• FRIESE MA, WISCHHUSEN J, WICK W et al.: RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. (2004) 64(20):7596-7603.
   PubMed Web of Science ®Google Scholar
• EL ANDALOUSSI A, HAN Y, LESNIAK MS: Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J. Neurosurg. (2006) 105(3):430-437.
   PubMed Web of Science ®Google Scholar
• FAKHRAI H, MANTIL JC, LIU L et al.: Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. (2006) 13(12):1052-1060.
   PubMed Web of Science ®Google Scholar
• KUWASHIMA N, NISHIMURA F, EGUCHI J et al.: Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J. Immunol. (2005) 175(4):2730-2740.
   PubMed Web of Science ®Google Scholar